
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
Fatima Amanat, Shirin Strohmeier, Raveen Rathnasinghe, et al.
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 79
Fatima Amanat, Shirin Strohmeier, Raveen Rathnasinghe, et al.
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 79
Showing 1-25 of 79 citing articles:
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1188-1200.e19
Open Access | Times Cited: 181
Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1188-1200.e19
Open Access | Times Cited: 181
Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 138
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 138
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
Per Johan Klasse, Douglas F. Nixon, John P. Moore
Science Advances (2021) Vol. 7, Iss. 12
Open Access | Times Cited: 110
Per Johan Klasse, Douglas F. Nixon, John P. Moore
Science Advances (2021) Vol. 7, Iss. 12
Open Access | Times Cited: 110
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Satoshi Ikegame, Mohammed Nure Alam Siddiquey, Chuan-Tien Hung, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 110
Satoshi Ikegame, Mohammed Nure Alam Siddiquey, Chuan-Tien Hung, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 110
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 105
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 105
SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines
John E. Bowen, Young‐Jun Park, Cameron Stewart, et al.
Science Immunology (2022) Vol. 7, Iss. 78
Open Access | Times Cited: 70
John E. Bowen, Young‐Jun Park, Cameron Stewart, et al.
Science Immunology (2022) Vol. 7, Iss. 78
Open Access | Times Cited: 70
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Payton A. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 56
Payton A. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 56
Virus vaccines: proteins prefer prolines
Rogier W. Sanders, John P. Moore
Cell Host & Microbe (2021) Vol. 29, Iss. 3, pp. 327-333
Open Access | Times Cited: 94
Rogier W. Sanders, John P. Moore
Cell Host & Microbe (2021) Vol. 29, Iss. 3, pp. 327-333
Open Access | Times Cited: 94
Status Report on COVID-19 Vaccines Development
Arun Kumar, William E. Dowling, Raúl Gómez Román, et al.
Current Infectious Disease Reports (2021) Vol. 23, Iss. 6
Open Access | Times Cited: 78
Arun Kumar, William E. Dowling, Raúl Gómez Román, et al.
Current Infectious Disease Reports (2021) Vol. 23, Iss. 6
Open Access | Times Cited: 78
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
Mathieu Claireaux, Tom G. Caniels, Marlon de Gast, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 57
Mathieu Claireaux, Tom G. Caniels, Marlon de Gast, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 57
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Edward R. Kastenhuber, Marisa Mercadante, Benjamin E. Nilsson-Payant, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 55
Edward R. Kastenhuber, Marisa Mercadante, Benjamin E. Nilsson-Payant, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 55
SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
Mijia Lu, Michelle Chamblee, Yuexiu Zhang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 35
Open Access | Times Cited: 44
Mijia Lu, Michelle Chamblee, Yuexiu Zhang, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 35
Open Access | Times Cited: 44
Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
Thayne H. Dickey, Wai Kwan Tang, Brandi Butler, et al.
Science Advances (2022) Vol. 8, Iss. 37
Open Access | Times Cited: 42
Thayne H. Dickey, Wai Kwan Tang, Brandi Butler, et al.
Science Advances (2022) Vol. 8, Iss. 37
Open Access | Times Cited: 42
The role of vaccines in the COVID-19 pandemic: what have we learned?
Florian Krammer
Seminars in Immunopathology (2023) Vol. 45, Iss. 4-6, pp. 451-468
Open Access | Times Cited: 38
Florian Krammer
Seminars in Immunopathology (2023) Vol. 45, Iss. 4-6, pp. 451-468
Open Access | Times Cited: 38
Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics
Sean M. Braet, Theresa SC Buckley, Varun Venkatakrishnan, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 28
Sean M. Braet, Theresa SC Buckley, Varun Venkatakrishnan, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 28
Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development
Qiaonan Hong, Jian Liu, Yuquan Wei, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1218-1218
Open Access | Times Cited: 26
Qiaonan Hong, Jian Liu, Yuquan Wei, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1218-1218
Open Access | Times Cited: 26
Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells
Matthew Stuible, Christian Gervais, Simon Lord‐Dufour, et al.
Journal of Biotechnology (2020) Vol. 326, pp. 21-27
Open Access | Times Cited: 62
Matthew Stuible, Christian Gervais, Simon Lord‐Dufour, et al.
Journal of Biotechnology (2020) Vol. 326, pp. 21-27
Open Access | Times Cited: 62
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
Daniel Watterson, Danushka K. Wijesundara, Naphak Modhiran, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 4
Open Access | Times Cited: 54
Daniel Watterson, Danushka K. Wijesundara, Naphak Modhiran, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 4
Open Access | Times Cited: 54
The way of SARS-CoV-2 vaccine development: success and challenges
Yetian Dong, Tong Dai, Bin Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 50
Yetian Dong, Tong Dai, Bin Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 50
Could live attenuated vaccines better control COVID-19?
Shinya Okamura, Hirotaka Ebina
Vaccine (2021) Vol. 39, Iss. 39, pp. 5719-5726
Open Access | Times Cited: 49
Shinya Okamura, Hirotaka Ebina
Vaccine (2021) Vol. 39, Iss. 39, pp. 5719-5726
Open Access | Times Cited: 49
Roles of the polybasic furin cleavage site of spike protein in SARS‐CoV‐2 replication, pathogenesis, and host immune responses and vaccination
Md. Golzar Hossain, Yan‐Dong Tang, Sharmin Akter, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 5, pp. 1815-1820
Closed Access | Times Cited: 48
Md. Golzar Hossain, Yan‐Dong Tang, Sharmin Akter, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 5, pp. 1815-1820
Closed Access | Times Cited: 48
SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
George Carnell, Katarzyna A. Ciazynska, David A. Wells, et al.
Journal of Virology (2021) Vol. 95, Iss. 15
Open Access | Times Cited: 41
George Carnell, Katarzyna A. Ciazynska, David A. Wells, et al.
Journal of Virology (2021) Vol. 95, Iss. 15
Open Access | Times Cited: 41
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant
Bassel Akache, Tyler M. Renner, Anh Tran, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 41
Bassel Akache, Tyler M. Renner, Anh Tran, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 41
SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms
Jiaqi Li, Huimin Jia, Miaomiao Tian, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 31
Jiaqi Li, Huimin Jia, Miaomiao Tian, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 31